Brain Tumor Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against brain tumor and guarantee the finest results for our customers all over the world.

Brain Tumor

Malignant brain tumors are classified into primary and secondary (metastatic) brain tumors. Despite recent advancements in conventional therapies, such as surgery, radiation therapy, and chemotherapy, the prognoses for these tumors remain dismal. A variety of immunotherapy clinical trials are being conducted for both primary and secondary malignant brain tumors, including vaccine, checkpoint blockade, adoptive cell transfer, and oncolytic virus approaches.

Primary Brain Tumors - Primary brain tumors can arise from any tissue in the central nervous system (CNS) and occur in around 250,000 people a year globally. Primary brain tumors are classified into benign and malignant tumors. Benign tumors are usually demarcated from the surrounding brain tissue and thus often totally resectable by surgery. In contrast, malignant brain tumors invade the surrounding CNS tissue and are highly resistant to therapy. Gliomas, tumors arising from glial tissues, are the most common malignant primary brain tumors, accounting for 27% of all primary brain tumors and 80% of malignant tumors.

Secondary (Metastatic) Brain Tumors - Secondary (metastatic) brain tumors are a common complication among patients with systemic cancer and more common than primary brain tumors. Lung and breast cancers and melanoma are responsible for up to threequarters of metastatic brain lesions. Clinically symptomatic metastases to the brain occur in 15% to 20% of patients with metastatic breast cancer.

Therapeutic Vaccines for Brain Tumor

Glioma is one of the most devastating cancers, affecting children and young adults, and associated with a very high morbidity and poor prognosis. The propensity of glioma cells to invade normal brain structures makes current treatments poorly efficient and new therapeutic strategies an urgent need. We now know that many of the rules governing immune responses in other tissues are also valid for the brain, providing solid scientific background for developing new strategies exploiting the immune system to fight brain tumors.

Creative Biolabs has an elite group of scientists who are focusing on development of brain tumor vaccines. Brain tumor vaccines offer a lifeline to patients with aggressive tumors, such as glioblastomas (GBM), that are hard to eliminate.

Our Brain Tumor Vaccine Platforms

Vaccines with Glioma-Associated Antigens - Antigens expressed in tumor cells can be classified into two general categories: (a) tumor-associated antigens and (b) tumor-specific antigens. Most antigens that have been evaluated in glioma vaccines to date are nonmutated, glioma-associated antigens.

Vaccines with Glioma-Specific Antigen - This direction is becoming particularly important as we gain access to more robust immunotherapy modalities. Therefore, targeting of recurrent and immunogenic mutations, such as EGFRvIII in GBM and isocitrate dehydrogenase (IDH) 1R132H mutations in secondary GBMs and lower-grade gliomas, represents safe and potentially effective approaches.

• EGFRvIII-Targeting Vaccines.
• Vaccines Against the Isocitrate Dehydrogenase Mutation-Derived Human Leucocyte Antigen-Class II Epitope.
• CMV-Derived Antigens: Viral antigens may represent particularly attractive targets for immunotherapy because they are foreign to the host immune system and thus are inherently immunogenic. Malignant brain tumors have not been shown to be virally induced, but studies have demonstrated frequent detection of low level expression of human CMV genes within malignant gliomas.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the brain tumor vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.